

Xbrane applies for admission to trading on Nasdaq Stockholm and publishes prospectus

On 17 September 2019 Xbrane Biopharma AB (publ) ("Xbrane" or the "Company"), published that Nasdaq Stockholm's listing committee has decided that the Company fulfills the requirements for admission to trading of the Company's shares on the main market Nasdaq Stockholm subject to customary provisions. The board of directors in Xbrane has today decided to apply for the company's shares to be admitted for trading on Nasdaq Stockholm. The board of directors in Xbrane has in connection thereof prepared a prospectus which today has been approved and registered by the Swedish Financial Supervisory Authority ("SFSA") (Sw. Finansinspektionen) and published on the Company's website.

The first day of trading of Xbrane's shares on Nasdaq Stockholm will be on Monday 23 September 2019. The last day of trading of Xbrane's shares on Nasdaq First North Growth Market will be on Friday 20 September 2019.

Shareholders of Xbrane do not need to take any action in connection with the change of listing venue.

The shares that will be admitted to trading on Nasdaq Stockholm will be traded under the same ticker, "XBRANE", and with the same ISIN code SE0007789409. No new shares will be issued in connection with the listing on Nasdaq Stockholm.

For further information, please refer to the prospectus prepared in connection with the listing on Nasdaq Stockholm, which today was approved and registered by the SFSA and be published on Xbrane's website (www.xbrane.com).

Advisors

Vator Securities is financial adviser and Baker McKenzie is legal adviser to the Company in connection with the change of listing venue

For more information, please contact:

Martin Åmark, CEO

M: +46 (0) 763-093 777

E: martin.amark@xbrane.com

Susanna Helgesen, CFO

M: +46 (0) 708-278 636

E: susanna.helgesen@xbrane.com

About Xbrane

Xbrane is a commercial phase Swedish biopharmaceutical company that develops, manufactures and produces biosimilars. Xbrane has a patented protein production platform for development of biosimilars and world leading expertise in biosimilars. Xbrane's headquarter is located in Solna

Press release
19 September 2019 09:30:00 CEST



*outside of Stockholm and the company's in-house research and development facilities are located in Sweden and Italy. Xbrane is listed at Nasdaq First North Growth Market since February 3rd, 2016 under the name XBRANE and Avanza Bank AB is Xbrane's certified adviser (corp@avanza.se, +46 (0)8 409 421 20). For more information *please visit www.xbrane.com.**

Attachments

[Xbrane applies for admission to trading on Nasdaq Stockholm and publishes prospectus](#)